(MedPage Today) — The FDA expanded the approval of ustekinumab (Stelara) in Crohn’s disease to include the treatment of kids as young as 2 years, Johnson & Johnson announced.
High clinical remission rates (98%) at approximately 5 years were…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
